Skip to main content
 

2015 Press Releases

Webcast ImageWebcast
Idera Pharmaceuticals, Inc. at Jefferies 2015 Global Healthcare Conference (Replay)
06/01/15 at 1:30 p.m. ET
Idera Pharmaceuticals, Inc. at Jefferies 2015 Global Healthcare Conference
Monday, June 1, 2015 1:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Webcast ImageWebcast
Idera Pharmaceuticals, Inc. at JMP Securities 2015 Life Sciences Conference (Live)
06/24/15 at 12:30 p.m. ET
Idera Pharmaceuticals, Inc. at JMP Securities 2015 Life Sciences Conference
Wednesday, June 24, 2015 12:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Keyword Search
 
2015 | 2014 | 2013 | 2012 | 2011
DateTitle 
05/27/15Idera to Present at Two June Investor Healthcare Conferences
CAMBRIDGE, Ma. and EXTON, Pa., May 27, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Vincent Milano, Idera's Chief Executive Officer will present a corporate update at the Jefferies 2015 Global Healthcare Conference on Monday, June 1, 2015 at 1:30 p.m. Eastern Time at the Grand Hyatt in New York City. Mr. Milano w... 
Printer Friendly Version
05/18/15Idera Pharmaceuticals Provides Development Update on IMO-9200, an Antagonist of Toll-like Receptors
Company Completed Phase 1 Trial in Healthy Subjects Which Demonstrated IMO-9200 Safe and Well-tolerated Across All Dose Regimens Pre-Clinical Data Supporting IMO-9200 as an Oral Therapeutic Option to Treat Inflammatory Bowel Disease Presented at 2015 Digestive Disease Week Conference CAMBRIDGE, Mass. and EXTON, Pa., May 18, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for ... 
Printer Friendly Version
05/11/15Idera Pharmaceuticals Reports First Quarter 2015 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass. and EXTON, Pa., May 11, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for oncology and rare diseases, today reported its financial and operational results for the first quarter ended March 31, 2015. "During the first quarter of this year, we continued to build momentum as we executed on our numerous clinical development programs f... 
Printer Friendly Version
04/13/15Idera to Present at the 14th Annual Needham Healthcare Conference
CAMBRIDGE, Mass. and EXTON, Pa., April 13, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Vincent Milano, Idera's Chief Executive Officer will present a corporate update at the 14th Annual Needham Healthcare Conference on Tuesday, April 14, 2015 at 1:40 p.m. Eastern Time at the Westin Grand Central Hotel in New York Ci... 
Printer Friendly Version
04/01/15Idera Announces FDA Orphan Drug Designation for IMO-8400 for the Treatment of Diffuse Large B-Cell Lymphoma
CAMBRIDGE, Mass. and EXTON, Pa., April 1, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for oncology and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for IMO-8400, an antagonist of the endosomal Toll-like receptors (TLRs) 7, 8 and 9, for the treatment of diffuse large B-cell lympho... 
Printer Friendly Version
03/12/15Idera Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass. and EXTON, Pa., March 12, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for oncology and rare diseases, today reported its financial and operational results for the fourth quarter and year ended December 31, 2014. "2014 was a year of transformation for Idera, as we focused our company on oncology and rare diseases," stated Vincent... 
Printer Friendly Version
02/23/15Idera to Present at Two Upcoming Investor Healthcare Conferences
CAMBRIDGE, Mass. and EXTON, Pa., Feb. 23, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Vincent Milano, Idera's Chief Executive Officer will present a corporate update at the 2015 RBC Capital Markets' Global Healthcare Conference on Wednesday February 25, 2015 at 9:00 a.m. Eastern Time at the New York Palace Hotel. ... 
Printer Friendly Version
02/19/15Idera Pharmaceuticals Announces Closing of Public Offering of Common Stock
CAMBRIDGE, Mass. and EXTON, Pa., Feb. 19, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA) ("Idera" or the "Company") today announced the closing of its previously announced underwritten public offering of 23,000,000 shares of common stock at an offering price of $3.75 per share. The shares of common stock in the offering include 3,000,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares at the offering price. The gross p... 
Printer Friendly Version
02/13/15Idera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass. and EXTON, Pa., Feb. 13, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA) ("Idera" or the "Company") today announced the pricing of an underwritten public offering of 20,000,000 shares of common stock for a public offering price of $3.75 per share. The Company has granted to the underwriters participating in the offering a 30-day option to purchase up to an additional 3,000,000 shares of common stock. All of the shares in the offering are to be sold by Idera. T... 
Printer Friendly Version
02/09/15Idera Pharmaceuticals Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass. and EXTON, Pa., Feb. 9, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA) ("Idera" or the "Company") today announced that it intends to offer and sell up to $75,000,000 of shares of its common stock in an underwritten public offering. In connection with this offering, Idera expects to grant the underwriters a 30-day option to purchase additional shares of common stock, equal to up to 15% of the number of shares of common stock sold in the offering. All of the sh... 
Printer Friendly Version
01/26/15Idera Announces Leadership Appointments
CAMBRIDGE, Mass. and EXTON, Pa., Jan. 26, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing immune-modulating and gene silencing therapies for cancer and rare diseases, today announced the appointments of R. Clayton Fletcher as Senior Vice President, Business Development and Strategic Planning, and Jim Baker as Executive Director, Market Development. Vincent J. Milano, President and Chief Executive Officer of Idera Pharm... 
Printer Friendly Version
01/09/15Idera to Present at the 33rd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. and EXTON, Pa., Jan. 9, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Vincent Milano, Idera's Chief Executive Officer will present a corporate update at the 33rd Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2015 at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time at the Westin St.... 
Printer Friendly Version

Contact

Please direct all general questions regarding Idera to:

Idera Pharmaceuticals, Inc.
167 Sidney Street
Cambridge, MA 02139

617-679-5500 tel
617-679-5592 fax

info@iderapharma.com